Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin ten Haaf

Showing results (11-20 of 57) with videos related to

Pageof 6
Sort By:
Eclinicalmedicine|May 30, 2024
Projected effectiveness of lung cancer screening and concurrent smoking cessation support in the NetherlandsKoen de Nijs, Kevin Ten Haaf, Carlijn van der Aalst, et al.
International Journal of Cancer|October 4, 2023
Cost-effectiveness of risk-based low-dose computed tomography screening for lung cancer in SwitzerlandYuki Tomonaga, Koen de Nijs, Heiner C Bucher, et al.
International Journal of Cancer|March 30, 2021
Personalising lung cancer screening: An overview of risk-stratification opportunities and challengesKevin Ten Haaf, Carlijn M van der Aalst, Harry J de Koning, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 10, 2015
Baseline Characteristics and Mortality Outcomes of Control Group Participants and Eligible Non-Responders in the NELSON Lung Cancer Screening StudyUraujh Yousaf-Khan, Nanda Horeweg, Carlijn van der Aalst, et al.
Journal of the National Cancer Institute|November 9, 2017
Quantifying Overdiagnosis in Cancer Screening: A Systematic Review to Evaluate the MethodologyTheodora M Ripping, Kevin Ten Haaf, André L M Verbeek, et al.
The Lancet Regional Health. Western Pacific|December 10, 2024
Targeted lung cancer screening in the age of immunotherapies and targeted therapies - an economic evaluation for AustraliaJacqueline Roseleur, Jonathan Karnon, Harry de Koning, et al.
Cancer|November 1, 2023
Assessing the impact of increasing lung screening eligibility by relaxing the maximum years-since-quit threshold: A simulation modeling studyRafael Meza, Pianpian Cao, Koen de Nijs, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 3, 2021
Cost-effectiveness Analysis of Breast Cancer Screening Using Mammography in Singapore: A Modeling StudySarocha Chootipongchaivat, Xin Yi Wong, Kevin Ten Haaf, et al.
International Journal of Cancer|November 24, 2025
Impact of lung cancer screening eligibility criteria on participants' characteristics and healthcare resourcesMaría Olivia Cabrera, Kevin Ten Haaf, Josep Maria Borràs, et al.
Cancer Medicine|August 19, 2019
All-cause mortality versus cancer-specific mortality as outcome in cancer screening trials: A review and modeling studyEveline A M Heijnsdijk, Marcell Csanádi, Andrea Gini, et al.
Pageof 6

Showing results (11-20 of 57) with videos related to

Sort By:
Pageof 6
Eclinicalmedicine|May 30, 2024
Projected effectiveness of lung cancer screening and concurrent smoking cessation support in the NetherlandsKoen de Nijs, Kevin Ten Haaf, Carlijn van der Aalst, et al.
International Journal of Cancer|October 4, 2023
Cost-effectiveness of risk-based low-dose computed tomography screening for lung cancer in SwitzerlandYuki Tomonaga, Koen de Nijs, Heiner C Bucher, et al.
International Journal of Cancer|March 30, 2021
Personalising lung cancer screening: An overview of risk-stratification opportunities and challengesKevin Ten Haaf, Carlijn M van der Aalst, Harry J de Koning, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 10, 2015
Baseline Characteristics and Mortality Outcomes of Control Group Participants and Eligible Non-Responders in the NELSON Lung Cancer Screening StudyUraujh Yousaf-Khan, Nanda Horeweg, Carlijn van der Aalst, et al.
Journal of the National Cancer Institute|November 9, 2017
Quantifying Overdiagnosis in Cancer Screening: A Systematic Review to Evaluate the MethodologyTheodora M Ripping, Kevin Ten Haaf, André L M Verbeek, et al.
The Lancet Regional Health. Western Pacific|December 10, 2024
Targeted lung cancer screening in the age of immunotherapies and targeted therapies - an economic evaluation for AustraliaJacqueline Roseleur, Jonathan Karnon, Harry de Koning, et al.
Cancer|November 1, 2023
Assessing the impact of increasing lung screening eligibility by relaxing the maximum years-since-quit threshold: A simulation modeling studyRafael Meza, Pianpian Cao, Koen de Nijs, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 3, 2021
Cost-effectiveness Analysis of Breast Cancer Screening Using Mammography in Singapore: A Modeling StudySarocha Chootipongchaivat, Xin Yi Wong, Kevin Ten Haaf, et al.
International Journal of Cancer|November 24, 2025
Impact of lung cancer screening eligibility criteria on participants' characteristics and healthcare resourcesMaría Olivia Cabrera, Kevin Ten Haaf, Josep Maria Borràs, et al.
Cancer Medicine|August 19, 2019
All-cause mortality versus cancer-specific mortality as outcome in cancer screening trials: A review and modeling studyEveline A M Heijnsdijk, Marcell Csanádi, Andrea Gini, et al.
Pageof 6